Blog

Brittney Abernathy: RAGE Signaling in Breast Cancer Progression and Metastasis by Coser et al.

health365.sg

Jan 11, 2025, 07:52

Brittney Abernathy: RAGE Signaling in Breast Cancer Progression and Metastasis by Coser et al.

Brittney Abernathy, Journal Manager at Frontiers in Nuclear Medicine, shared a post on LinkedIn:

“New Year means new research!

New Review: RAGE Signaling in Breast Cancer Progression and Metastasis
A fascinating scoping review by Coser et al. examines the critical role of the Receptor for Advanced Glycation End Products (RAGE) and its ligands in breast cancer progression.

Highlights:

RAGE activation by ligands (AGEs, HMGB1, S100 proteins) enhances downstream signaling pathways (PI3K/AKT, JAK/STAT, RAS/MAPK), promoting tumor growth and metastasis

Meta-analysis revealed RAGE rs1800624 polymorphism may increase breast cancer risk in Asian populations

High dietary AGE intake correlates with increased breast cancer risk and mortality, particularly in postmenopausal women

HMGB1-RAGE interaction promotes tumor microenvironment remodeling and cancer-associated fibroblast activation

S100 proteins (especially S100A4, S100A7, S100A8/A9) show promise as prognostic biomarkers

Therapeutic Implications:

RAGE antagonists (RP7, TTP488, FPS-ZM1) demonstrate potential in reducing TNBC metastasis

Targeting RAGE-ligand interactions could overcome therapy resistance

Monitoring AGE/sRAGE ratios may improve risk stratification

Given the complex interplay between RAGE signaling and the tumor microenvironment, could combining RAGE inhibitors with existing immunotherapies provide a breakthrough for treating aggressive breast cancer subtypes?

Read the full article here.”

RAGE and its ligands in breast cancer progression and metastasis

Authors: Madalina Coser et al.